(The Hill) — The Food and Drug Administration (FDA) announced Thursday the approval of both Pfizer’s and Moderna’s updated ...

The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Drug developers Moderna Thursday filed for clearance from the US Food and Drug Administration (FDA) to extend the use of their COVID-19 vaccine to children aged 6 months to 5 years, it was announced.

Currently, Moderna boosters have only been approved for certain people with weakened immune systems, such as cancer patients or transplant recipients. FDA Ruling: The FDA approved people 65 and ...

Moderna has asked the FDA for emergency use authorisation for ... while Moderna is going for a broad approval in all adults. In a statement, Moderna said the request to include all over-18s ...

Moderna is most well known for its Covid-19 vaccine, which is called Spikevax. The most recent version of Spikevax was approved by the U.S. Food and Drug Administration in August ahead of the fall ...

United States health authorities Monday gave full approval to the COVID-19 vaccine developed by Pfizer-BioNTech, which will now be marketed under the Comirnaty brand. Moderna's drug is expected to ...

Moderna’s drug is a lot less problematic when it comes ... extended stability conditions for mRNA-1273 to regulators for approval. The ability to store our vaccine for up to 6 months at -20 ...

These mutations negatively affected the effectiveness of the original vaccines and prompted drug ... Moderna and Pfizer-BioNTech converted their vaccines from monovalent to bivalent. Approved ...